MyFinsight
Home
About
Contact
zyme: the income statement
Download
Download image
Unrealized income on
available for sale...
$0.29M
(-84.78%↓ Y/Y)
Comprehensive loss
-$19.312M
(30.89%↑ Y/Y)
Total other
comprehensive income
$0.29M
(-84.78%↓ Y/Y)
Net loss
-$19.602M
(34.33%↑ Y/Y)
Other income
(expense), net (note 10)
$0.315M
(254.41%↑ Y/Y)
Interest income
$3.529M
(-26.25%↓ Y/Y)
Income tax expense
$1.336M
(491.15%↑ Y/Y)
Loss before income
taxes
-$18.266M
(38.34%↑ Y/Y)
Total other income,
net
$3.844M
(-16.09%↓ Y/Y)
Merck Sharp Dohme
LLC-Research Period...
$0.25M
Johnson Johnson
Innovative...
$25M
Be One Medicines
Ltd.-Royalty
$0.14M
Jazz-Royalty
$0.831M
Drug Supply-Jazz
$0.071M
Drug Supply For
Ongoing Studies-Jazz
$0.97M
Jazz-Research Support
Payments And Other...
$0.352M
Loss from operations
-$22.11M
(35.36%↑ Y/Y)
Research and development
collaborations (note 9)
$27.614M
(72.59%↑ Y/Y)
Total operating
expenses
$49.724M
(-0.96%↓ Y/Y)
General and
administrative
$14.146M
(2.12%↑ Y/Y)
Research and development
$35.578M
(-2.13%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME)